Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "EPS"

550 News Found

FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026
News | February 07, 2026

FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026

Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy


Revvity posts higher Q4 earnings, lifts 2026 outlook as diagnostics strength offsets margin pressure
News | February 05, 2026

Revvity posts higher Q4 earnings, lifts 2026 outlook as diagnostics strength offsets margin pressure

Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come


AbbVie posts higher revenue in 2025, led by immunology & neuroscience growth
News | February 05, 2026

AbbVie posts higher revenue in 2025, led by immunology & neuroscience growth

Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,


FDA launches PreCheck program to bring drug manufacturing back to US
News | February 04, 2026

FDA launches PreCheck program to bring drug manufacturing back to US

The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites


Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research
R&D | February 04, 2026

Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research

The new service delivers end-to-end support, managing every stage of an epigenomics project


Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY
News | February 02, 2026

Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY

Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%


Dr Lal PathLabs reports Q3 revenue of Rs 660 crore, posts strong growth amid labour code impact
News | February 02, 2026

Dr Lal PathLabs reports Q3 revenue of Rs 660 crore, posts strong growth amid labour code impact

The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up


Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
Policy | February 01, 2026

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave


Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
News | January 30, 2026

Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%

The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year


Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India
Drug Approval | January 24, 2026

Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India

Company to launch product after the expiry of semaglutide patent in India